Sermorelin
Sermorelin: its history as the approved drug Geref, why it was discontinued, its status today and what the evidence covers.
Formerly approved, now compounded · Evidence grade C · Reviewed
Sermorelin (Geref (discontinued)). Growth-hormone-releasing hormone analog.
CFormerly approved, now compounded. Evidence grade C: limited, early or dated human data.
What is Sermorelin?
Sermorelin is a fragment of the hormone that signals the pituitary gland to release growth hormone.
Is Sermorelin FDA-approved?
It was approved in 1997 as Geref for growth hormone deficiency in children. The maker discontinued it in 2008 and FDA later confirmed the withdrawal was not for safety or effectiveness reasons. No FDA-approved sermorelin product is on the market today. It is obtained through compounding pharmacies on prescription.
What does the evidence show for Sermorelin?
Real human data from its years as an approved pediatric drug. Evidence for the adult uses promoted today is limited, with little long-term outcome data.
What are the known risks of Sermorelin?
Compounded products are not FDA-approved, so quality depends on the pharmacy.
How is Sermorelin measured?
Usually dispensed as a powder vial. The Mix mode converts the prescribed dose into syringe units.
Sources: Portrait: is sermorelin FDA approved. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.